Login / Signup

Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.

Min Kyung ParkYun Bin LeeHyemi MoonNa Ryung ChoiMinseok Albert KimHeejoon JangJoon Yeul NamEun Ju ChoJeong-Hoon LeeSu Jong YuYoon Jun KimJung-Hwan Yoon
Published in: Digestive diseases and sciences (2022)
The effectiveness of lenvatinib and sorafenib was comparable for the treatment of unresectable HCC in decompensated patients.
Keyphrases
  • ejection fraction
  • randomized controlled trial
  • end stage renal disease
  • systematic review
  • heart failure
  • newly diagnosed
  • locally advanced
  • chronic kidney disease
  • liver metastases
  • radiation therapy
  • rectal cancer